Join Now

Category Archives: BioUtah News

Sen. Romney Opposes Drug Importation as the Senate HELP Committee Advances User Fees

By Natalie Themm | Published June 16, 2022

The Senate Health, Education, Labor and Pensions (HELP) Committee voted 13 to 9 on Tuesday to advance user fee reauthorization legislation.

Also posted in Policy News | | Leave a comment

Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184

By Natalie Themm | Published June 15, 2022

HT-6184 is a novel NEK7/NLRP3 inhibitor

| Tagged | Leave a comment

BD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveillance, Drive Innovation for Patient Care

By Natalie Themm | Published June 15, 2022

BD is among the first companies to enter innovative partnership with Mayo Clinic Platform for access to world’s largest collection of clinical data

| Tagged | Leave a comment

University of Manchester Adds Carterra’s LSA® Instrument for High-Throughput Antibody Screening and Characterization

By admin | Published June 9, 2022

MANCHESTER, England & SALT LAKE CITY–(BUSINESS WIRE)–The University of Manchester, United Kingdom, and Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, announced today that the University of Manchester has added Carterra’s LSA instrument to its Biomolecular Analysis Core Facility (BACF) within the Faculty of Biology, Medicine and Health (FBMH). The BACF was […]

| Leave a comment

Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis

By admin | Published June 9, 2022

CAMBRIDGE, Mass., June 8, 2022 /PRNewswire/ — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food Drug and Administration (FDA) granted Orphan Drug Designation for TP-3654, the company’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis. “This designation is an important milestone in […]

| Leave a comment

ELEVAR THERAPEUTICS SHARES RESULTS OF PHASE 2 RIVOCERANIB TRIAL IN PATIENTS WITH PROGRESSIVE RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA

By admin | Published June 9, 2022

CHICAGO, June 06, 2022 — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today detailed the results of its Phase 2 clinical trial (Study RM-202) of rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), in patients with progressive recurrent […]

| Leave a comment

CerTest Biotec and BD Announce Collaboration on Molecular Diagnostic Test for Monkeypox

By Natalie Themm | Published June 8, 2022

CerTest Biotec Uses the BD MAX™ Molecular Diagnostic System Open System Reagent Suite to Develop RT-PCR Detection Kit

| Tagged | Leave a comment

BD TO ACQUIRE PARATA SYSTEMS TO ENTER NEW PHARMACY AUTOMATION SOLUTIONS MARKET

By Natalie Themm | Published June 7, 2022

Expands BD Transformative Solutions to Provide New Pharmacy Automation Technologies for Hospitals, Retail Pharmacy, Long-Term Care and Home Settings Advances BD 2025 Strategy to Accelerate Innovation in Smart, Connected Care and Enable New Care Settings Expected to be Immediately Accretive to Revenue Growth, Adjusted Operating Margins and Adjusted EPS; Enhances Ability to Achieve Long-Range Sales […]

| Tagged | Leave a comment

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

By Natalie Themm | Published June 6, 2022

Data shared in oral presentation at American Diabetes Association 82nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease

| Tagged | Leave a comment

PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

By Natalie Themm | Published June 6, 2022

PolarityTE announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor

| Tagged | Leave a comment

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative

By Natalie Themm | Published June 6, 2022

Profil has conducted over 30 biosimilar insulin trials and is the leading clinical research organization for studies related to diabetes.

| Tagged | Leave a comment

Biomerics announces expansion in Ireland with a new facility in Galway

By Natalie Themm | Published May 31, 2022

BIOMERICS ANNOUNCES EXPANSION INTO IRELAND Expanding High-Performance Balloon Design & Development Capabilities in Galway

| Tagged | Leave a comment

A Special Thanks To Our Legacy and Platinum Elite Members